Alemtuzumab
- PDF / 169,439 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 42 Downloads / 160 Views
1
S
Urticaria, erythema multiforme and herpes zoster ophthalmicus: 3 case reports In a single centre, retrospective study of 19 patients, 3 patients [ages and sexes not stated] were described, who developed urticaria (n=1), erythema multiforme (n=1) and herpes zoster ophthalmicus (n=1) during treatment with alemtuzumab for relapsing-remitting multiple sclerosis [routes, dosages and durations of treatment to reactions onset not stated]. The patients, who had a history of relapsing-remitting multiple sclerosis, had been receiving treatment with natalizumab. The therapy with natalizumab was switched to alemtuzumab. Out of the 3 patients, one patient developed urticaria, one patient developed erythema multiforme and the remaining patient developed herpes zoster ophthalmicus during alemtuzumab treatment [outcomes not stated]. Author comment: "Adverse events were in keeping with the known side effect profile of alemtuzumab." "There was one case of herpes zoster opthalimicus." John N, et al. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 90: 1376-1378, No. 12, Dec 2019. Available from: URL: http://doi.org/10.1136/ 803441017 jnnp-2019-320687 - United Kingdom
0114-9954/19/1784-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Dec 2019 No. 1784
Data Loading...
